Ann: Share Purchase Plan Closing Date Extended, page-598

Hi Batty,

I agree in part, and hence why I participated.

Absolutely PH will find a way to spin this and say it was a success and they go the capital they were after.

They need $65M over three years. But they don't need it tomorrow. And arguably there is spare money in the current $150M Kitty.

That being said they now employ 100 people and have 6 IP in trial, and as they make progress updates with Azer Cel. Will need to make additional progress payments to precision bio.
It's too big now to run the cash balances down low. To attract and secure talented people the company needs to show it has a future.

Going forward they'll need to keep the machine very well funded. Unless Hervaxx surprises, there is no commerical deals in the 12 month horizon. We're looking at CF33, Vaxxina, and Azer Cel to pay in 2026. In theory they have the money to last 3 years, but they won't want to arrive at the finish line without cash in reserve.

Hopefully they get the $30M from Retail or practically close. (In theory $1000 per holder).